PDF DatasheetHuman, Rat, and Broad Species Reactivity Anti-PGP9.5 / UchL1 Antibody Product Attributes
PGP9.5 / UchL1 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-UCHL1 antibody staining is expected to be primarily localized to the cytosol and nucleoplasm. There is variability in either the signal strength or the localization of signal in cytosol from cell to cell.
Observed Antibody Staining Data By Tissue Type:
Variations in PGP9.5 / UchL1 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in neuronal cells in the caudate nucleus, cells in the molecular layer in cerebellum, Purkinje cells in the cerebellum, neuronal cells in the cerebral cortex, peripheral nerve/ganglion in colon, neuronal cells in the hippocampus, cells in the tubules in kidney and islets of Langerhans in pancreas. More moderate antibody staining intensity was present in neuronal cells in the caudate nucleus, cells in the molecular layer in cerebellum, Purkinje cells in the cerebellum, neuronal cells in the cerebral cortex, peripheral nerve/ganglion in colon, neuronal cells in the hippocampus, cells in the tubules in kidney and islets of Langerhans in pancreas. Low, but measureable presence of PGP9.5 / UchL1 could be seen in cells in the seminiferous ducts in testis and Leydig cells in the testis. We were unable to detect PGP9.5 / UchL1 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of PGP9.5 / UchL1 expression as measured by anti-PGP9.5 / UchL1 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | + | – | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| UCHL1 Variability | + | +++ | + | + | + | ++ | + | + | ++ | + | + | + | + | + | + | + | + | ++ | + | + |
| PGP9.5 / UchL1 General Information | |
|---|---|
| Alternate Names | |
| Ubiquitin carboxy-terminal hydrolase L1, UCHL1 | |
| Molecular Weight | |
| 20-30kDa | |
| Chromosomal Location | |
| 4p13 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | UCHL1 |
| Entrez Gene ID | 7345 |
| Ensemble Gene ID | ENSG00000154277 |
| RefSeq Protein Accession(s) | NP_004172 |
| RefSeq mRNA Accession(s) | NM_004181, |
| RefSeq Genomic Accession(s) | NC_018915, NG_012931, NC_000004 |
| UniProt ID(s) | V9HW74, P09936 |
| UniGene ID(s) | V9HW74, P09936 |
| HGNC ID(s) | 12513 |
| Cosmic ID(s) | UCHL1 |
| KEGG Gene ID(s) | hsa:7345 |
| PharmGKB ID(s) | PA37160 |
| General Description of PGP9.5 / UchL1. | |
| This MAb reacts with a protein of 20-30kDa, identified as PGP9.5, also known as ubiquitin carboxyl-terminal hydrolase-1 (UchL1). Initially, PGP9.5 expression in normal tissues was reported in neurons, neuroendocrine cells but later it was found in distal renal tubular epithelium, spermatogonia, Leydig cells, oocytes, melanocytes, prostatic secretory epithelium, ejaculatory duct cells, epididymis, mammary epithelial cells, Merkel cells,, dermal fibroblasts. Furthermore, immunostaining for PGP9.5 has been shown in a wide variety of mesenchymal neoplasms as well. A mutation in PGP9.5 gene is believed to cause a form of Parkinson’s disease. | |
There are no reviews yet.